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Biomarkers are ‘objectively measured and evaluated indi-
cators of normal biological processes, pathogenic processes or
pharmacologic responses to a therapeutic intervention’ that
identify increased or decreased risk of patient benefit or
harm [1]. Imaging biomarkers (IB) are integral to cancer
healthcare and research. In oncology, patient manage-
ment relies heavily on using ordered categorical IBs to
stage patients (e.g. assignation of T, N and M status)
and to monitor therapeutic efficacy (e.g. objective
response, measured by RECIST 1.1 or equivalent cri-
teria) [2,3]. IBs are also used to measure toxicity in can-
cer patients. For example, SPECT quantification of
cardiac ejection fraction is an important biomarker of
drug-induced cardiotoxicity [4].
The role of IBs in oncology continues to increase in
the era of personalised medicine. Every year thousands
of imaging studies develop IBs and test their role as
putative prognostic, predictive, monitoring and radiation
planning biomarkers - both for use in healthcare and in
clinical trials of novel drug or radiotherapy treatments
[5]. Some IBs modify existing metrics. For example,
basing response criteria largely on 18F-FDG PET signal
changes rather than size changes (as in PERCIST v
RECIST) may stratify patients differently but still uses
the same conceptual biomarker, namely objective
response [6].
In distinction, many other IBs derive parameters that
measure novel aspects of tumour molecular biology,
pathophysiology or structural morphology. These IBs are
usually designed to quantify an unmet clinical need, such
as the hallmarks of cancer that are targets for drug devel-
opment. Examples include optical imaging of deoxy-Hb
and oxy-Hb ratios as a biomarker of hypoxia; measuring
13C-bicarbonate/CO2 ratios through dynamic nuclear
polarisation to map tumour pH; measuring changes in
glucose metabolism through quantifying percentage
reduction in 18F-FDG PET SUVmax ; measuring changes
in vascular function through quantifying percentage
reduction in Ktrans; or measuring tumour heterogeneity
by texture, fractal or other feature-based analyses [7-9].
Unfortunately, translation of new IBs has been disap-
pointing. Quantitative IBs in particular have been slow to
cross the translational gaps to become useful decision mak-
ing tools in drug development (pharmacodynamic or PD
IB) or in altering healthcare (as companion diagnostics, or
for screening, response, monitoring or outcome). The key
reason that IBs have failed to make substantial impact is
the lack of clear roadmap for IB validation and qualifica-
tion. IBs have several important differences from the more
familiar biospecimen-derived biomarkers and require a dif-
ferent validation roadmap tailored to the strengths and lim-
itations of IB. Recognising this need, Cancer Research UK
and the European Organization for Research and Treat-
ment of Cancer (EORTC) have sponsored an international
consensus effort to devise a roadmap and produce key
recommendations for the design, performance, governance
and publication of future IB studies [10].
This talk aims to:
1. Challenge delegates in their understanding of what
constitutes an IB
2. Introduce current thinking around how IBs should be
validated and qualified (the ‘imaging biomarker roadmap
for use in cancer studies’)
3. Provide a range of examples that highlight the
successes and failures of many popular and emerging IBs
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